The Center for Disease Dynamics, Economics & Policy (CDDEP) provides an interactive map here:http://resistancemap.cddep.org/

The data are illuminating and should cause some concern as we look at the growing resistance. There is also hope in noting the prevention of this issue to a large degree by key countries where policy is enforced and use is seen differently, with the consumer not driving the “drug bus”, rather an informed physician guided by long range policy.

We have to start globally funding increased R&D here before it’s too late. Over time, due to heavy use and natural evolution of bacteria, we have seen a significant increase in resistant strains that defy standard treatment courses. This is coupled with regulatory approval pressures and economic pressures that are reducing the innovation and funding for new antibiotic research. As these two trends converge, a crisis is brewing that we need to address.

Read a related article here: http://n.pr/1KmJoth